PRESS-RELEASE ·Filed Aug 31, 2026
Press release · Offering
Actionable Insight ▼ Bearish
Expected near-term dilution; monitor the prospectus supplement for size and pricing.
Latest settled — T+20d ⚠ clustered
PMVP ▲ +29.46% at T+20d
SHORT call ✗ call lost -29.46% · α vs SPY -29.14% · entry $1.29 → $1.67
Latest observation: T+37 +1.06% FF3 residual α
T+1d
-2.33%
call +2.33% · α +2.77%
$1.26
settled 8w ago
T+5d
+6.59%
call -6.59% · α -6.51%
$1.38
settled 7w ago
T+20d
+29.46%
call -29.46% · α -29.14%
$1.67
settled 27d ago
T+60d
Pending
in 29d
Price Chart
Loading chart...
Executive Summary
PMV Pharma commences an underwritten public offering of common stock, pre-funded warrants, and warrants. The offering size and terms are undisclosed, and TD Cowen is sole bookrunner.
Key Facts
- PMV Pharma commenced an underwritten public offering of common stock, pre-funded warrants, and common stock warrants.
- All securities in the offering are to be sold by PMV Pharma; no secondary selling shareholders.
- TD Cowen is sole book-running manager.
- Offering size, pricing, and terms are undisclosed.
- Offering is subject to market conditions; no assurance of completion.
- Filing is a press release under an existing effective shelf registration statement (Form S-3).
Financial Impact
Undisclosed dollar amount; dilutive to existing shareholders for a $65M market-cap company; prior similar offerings by pre-commercial biotechs typically raise $10M–$30M range.
dilutionoutstanding share count
Risk Factors
- Offering size could be material given $65M market cap, causing heavy dilution.
- No completed terms yet — market may react negatively to uncertainty and dilutive signal.
- PMVP is pre-revenue (precision oncology), lacks fundamental revenue to offset dilution.
Market Snapshot
Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
92% bullish (12 analysts)
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3353673 |
11 reports for PMVP
60% Hit rate @ T+20 Went positive at some point 4 of 6 best @ T+20▲ +29.46%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 5, 2026 21d ago | 8-K | $1.78 | awaiting T+20 | — | $1.13 (−36.80%) |
Aug 31, 2026 7w ago | Press Release | $1.29 $1.67 | ▼ −29.46% | ▼ −29.14% | $1.13 (+12.79%) |
Aug 31, 2026 7w ago | 8-K | $1.29 $1.67 | ▲ +29.46% | ▲ +29.14% | $1.13 (−12.79%) |
Aug 31, 2026 7w ago | Press Release | $1.29 $1.67 | ▼ −29.46% | ▼ −29.14% | $1.13 (+12.79%) |
Aug 31, 2026 7w ago | Press Release | $1.29 $1.67 | ▲ +29.46% | ▲ +29.14% | $1.13 (−12.79%) |
Aug 14, 2026 10w ago | 8-K | $1.26 $1.46 | ▲ +15.87% | ▲ +17.86% | $1.13 (−10.71%) |
Aug 14, 2026 10w ago | Press Release | $1.26 $1.46 | ▲ +15.87% | ▲ +17.86% | $1.13 (−10.71%) |
May 12, 2026 23w ago | 8-K | $1.42 $1.06 | ▼ −25.35% | ▼ −23.62% | $1.13 (−20.77%) |
May 12, 2026 23w ago | Press Release | $1.42 $1.06 | ▼ −25.35% | ▼ −23.62% | $1.13 (−20.77%) |
Apr 22, 2026 26w ago | DEFA14A | $1.48 $1.31 | ▼ −11.49% | ▼ −14.65% | $1.13 (−23.99%) |
Showing 10 of 11
US Market Status
Market Open — Closes in 19m
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers